

**ANTIDEPRESSANTS****Drug(s) Applied:**

FETZIMA; EMSAM; VENLAFAXINE 112.5 MG; AUVELITY

<b>ST Criteria</b>	Trial of two generics of the following formulary products: bupropion, mirtazapine, citalopram (tablet or solution), desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline (tablet or solution), venlafaxine. Approve for continuation of prior therapy.
--------------------	--

**ATYPICAL ANTIPSYCHOTICS****Drug(s) Applied:**

FANAPT; FANAPT TITRATION PACK; VRAYLAR; LYBALVI; SECUADO

<b>ST Criteria</b>	Trial of two of the following oral generic formulary atypical antipsychotic agents: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone. Approve for continuation of prior therapy.
--------------------	---

**GLUCAGON****Drug(s) Applied:**

GLUCAGEN

<b>ST Criteria</b>	Trial of one of the following: Gvoke, Baqsimi, or Glucagon.
--------------------	---

**INHALED CORTICOSTEROID****Drug(s) Applied:**

QVAR REDIMALER

<b>ST Criteria</b>	Trial of Arnuity Ellipta and either Flovent Diskus or Flovent HFA.
--------------------	--

**INVEGA HAFYERA THERAPY****Drug(s) Applied:**

INVEGA HAFYERA

<b>ST Criteria</b>	Trial of one of the following: Invega Sustenna or Invega Trinza. Step applies to new starts only. Approve for continuation of prior therapy.
--------------------	--

**NAMZARIC****Drug(s) Applied:**

NAMZARIC

<b>ST Criteria</b>	Trial of generic memantine extended-release.
--------------------	--

**NON-PREFERRED SGLT2S****Drug(s) Applied:**

INVOKAMET; INVOKAMET XR; INVOKANA

<b>ST Criteria</b>	Trial of Farxiga or Xigduo XR, AND one of the following: Jardiance, Synjardy, Synjardy XR. Step requirements do not apply to members with type 2 diabetes with either diabetic nephropathy or established cardiovascular disease.
--------------------	---

**RELISTOR****Drug(s) Applied:**

RELISTOR (TABLET, INJECTION)

<b>ST Criteria</b>	Trial of one of the following: lubiprostone, lactulose, Generalac, Constulose, or Enulose.
--------------------	--



**RYTARY****Drug(s) Applied:**

RYTARY

<b>ST Criteria</b>	Trial of one generic carbidopa/levodopa containing formulation.
--------------------	---

**ACTINIC KERATOSIS****Drug(s) Applied:**

DICLOFENAC 3% GEL; KLISYRI OINTMENT

<b>ST Criteria</b>	Trial of either topical fluorouracil or topical imiquimod.
--------------------	--

**STATINS****Drug(s) Applied:**

LIVALO

<b>ST Criteria</b>	Trial of any one of the following generic formulary HMG-CoA reductase inhibitors (statin): atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin
--------------------	--

## GLP1 AGONISTS

**Drug(s) Applied:**

VICTOZA; OZEMPIC; TRULICITY; RYBELSUS; MOUNJARO

<b>ST Criteria</b>	Trial of one of the following generic formulary metformin or metformin combinations: metformin, metformin ER, glipizide-metformin, glyburide-metformin, pioglitazone-metformin. Ozempic (semaglutide), Trulicity (dulaglutide), Victoza (liraglutide): Step requirements do not apply to members with type 2 diabetes and multiple cardiovascular risk factors or established cardiovascular disease.
--------------------	---

**ZONISADE SUSPENSION****Drug(s) Applied:**

ZONISADE ORAL SUSPENSION

<b>ST Criteria</b>	Trial of generic zonisamide capsule. Step applies to new starts only. Approve for continuation of prior therapy.
--------------------	--